https://www.biospace.com/article/releases/theracosbio-announces-fda-approval-of-brenzavvy-bexagliflozin-for-the-treatment-of-adults-with-type-2-diabetes/
0
0
TheracosBio Announces FDA Approval of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes - BioSpace
1/23/23 at 1:31pm
Organization
BioSpace
Author
BioSpace
Details
41 words
Summarize
Health Drugs & Medications bexagliflozin BrenzavvyTM BioSpace TheracosBio TheracosBio FDA SGLT2
TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Create an account or login to join the discussion